Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular oncology"
DOI: 10.1002/1878-0261.13178
Abstract: Failure of colorectal cancer (CRC) treatment is due to residual disease, and its timely identification is critical for patient survival. Detecting CRC-associated mutations in patient circulating cell-free DNA is confounded by tumor mutation heterogeneity, requiring… read more here.
Keywords: tumor; tumor burden; treatment; bcat1 ikzf1 ... See more keywords
Detection of recurrent colorectal cancer with high specificity using a reporting threshold for circulating tumor DNA methylated in BCAT1 and IKZF1
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34159
Abstract: A blood assay measuring methylated BCAT1 and IKZF1 can detect recurrent colorectal cancer (CRC) with high sensitivity but suboptimal specificity. This study aimed to establish an upper reference limit (URL) of these biomarkers in a… read more here.
Keywords: methylated bcat1; recurrent colorectal; colorectal cancer; bcat1 ikzf1 ... See more keywords
Specificity of methylated BCAT1 and IKZF1 for colorectal cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.580
Abstract: 580Background: Methylated BCAT1 and IKZF1 are useful circulating tumor DNA (ctDNA) biomarkers for detection and following the course of colorectal cancer (CRC). This study aimed to determine the specificity of methylated BCAT1/IKZF1 for CRC detection… read more here.
Keywords: methylated bcat1; bcat1 ikzf1; colorectal cancer; specificity methylated ... See more keywords